Flow cytometric analysis is often integral to the swift and accurate diagnosis of leukemias and lymphomas of the blood, bone marrow, and lymph nodes. However, in the fast-moving and expanding field of clinical hematology, in can be challenging to remain up to speed with the latest biological research and technological innovations. Flow Cytometry of Hematological Malignancies has been designed to provide all those working in hematological oncology with a practical, cutting-edge handbook, featuring clear and fully illustrated guidance on all aspects of cytometry’s role in diagnosis and analysis. This essential second edition includes:
Explorations of more than 70 antigens
Full-color illustrations throughout
New descriptions of recently discovered markers
WHO classifications of hematological neoplastic diseases
Helpful tips for result interpretation and analysis
Featuring all this and more, Flow Cytometry of Hematological Malignancies, Second Edition, is an invaluable resource for both trainee and experienced hematologists, hematopathologists, oncologists, and pathologists, as well as medical students and diagnostic lab technicians.
CONTENTS
Foreword to the First Edition by Maryalice Stetler-Stevenson
Foreword to the First Edition by Bruno Brando
Foreword to the Second Edition by Michael J Borowitz
Preface to the First Edition
Preface to the Second Edition
1 ANTIGENS
Clustered (CD) Antigens
CD1 Antigens, XX
CD2 Antigen, XX
CD3 Antigen, XX
CD4 Antigen, XX
CD5 Antigen, XX
CD7 Antigen, XX
CD8 Antigen, XX
CD10 Antigen, XX
CD11b Antigen, XX
CD11c Antigen, XX
CD13 Antigen, XX
CD14 Antigen, XX
CD15 Antigen, XX
CD16 Antigen, XX
CD19 Antigen, XX
CD20 Antigen, XX
CD22 Antigen, XX
CD23 Antigen, XX
CD24 Antigen, XX
CD25 Antigen, XX
CD26 Antigen, XX
CD27 Antigen, XX
CD28 Antigen, XX
CD30 Antigen, XX
CD33 Antigen, XX
CD34 Antigen, XX
CD38 Antigen, XX
CD43 Antigen, XX
CD45 Antigen, XX
CD45 Isoforms, XX
CD48 Antigen, see SLAM molecules, XX
CD49 Antigens, XX
CD56 Antigen, XX
CD57 Antigen, XX
CD61 Antigen, XX
CD62L Antigen, XX
CD64 Antigen, XX
CD65 Antigen, XX
CD66c Antigen, XX
CD71 Antigen, XX
CD79 Antigen, XX
CD81 Antigen, XX
CD84 Antigen, see SLAM molecules, XX
CD103 Antigen, XX
CD123 Antigen, XX
CD117 Antigen, XX
CD138 Antigen, XX
CD150 Antigen, see SLAM molecules, XX
CD158 Antigen, see KIRs, XX
CD181-186, 191-199 Antigens, see Chemokines and Chemokine Receptors, XX
CD200 Antigen, XX
CD229 Antigen, see SLAM molecules, XX
CD244 Antigen, see SLAM molecules, XX
CD280-290 Antigens, see Toll-like Receptors, XX
CD305 Antigen, XX
CD307 (IRTA) Antigen Family, XX
CD319 Antigen, see SLAM molecules, XX
CD352-353 Antigens, see SLAM molecules, XX
CD371 Antigen, XX
Non clustered (or primarily known with other names) antigens
Bcl-2 Protein, XX
Chemokines and Chemokine Receptors, XX
CRLF2, XX
Cytotoxic Proteins, XX
HLA-DR Antigen, XX
Immunoglobulins, XX
KIR, CD158 Isoforms, XX
Myeloperoxidase (MPO), XX
NG2 Antigen, XX
PCA-1 Antigen, XX
ROR-1 Antigen, XX
SLAM Molecules and SLAM Associated Protein (SAP), XX
SOX11, XX
T-cell Receptor (TCR), XX
Terminal Deoxy-nucleotidyl Transferase (TdT), XX
Toll-like Receptors (TLR), XX
VS38 Antigen, XX
ZAP-70 Protein, XX
2 DISEASES
Myeloproliferative neoplasms, XXX
Chronic myeloid leukemia (CML), XXX
Myeloproliferative neoplasms other than CML, XXX
Chronic neutrophilic leukemia (CNL), XXX
Polycythemia vera (PV), XXX
Primary myelofibrosis (PMF), XXX
Essential thrombocythemia (ET), XXX
Chronic eosinophilic leukemia (CEL), XXX
Mastocytosis, XXX
Acute masT-cell leukemia (AMCL), XXX
Chronic masT-cell leukemia (CMCL), XXX
Myelomastocytic leukemia (MML), XXX
Myelodysplastic/myeloproliferative neoplasms, XXX
Chronic myelomonocytic leukemia (CMML), XXX
Other myelodysplastic/myeloproliferative neoplasms and related conditions, XXX
Juvenile myelomonocytic leukemia (JMML), XXX
Atypical CML bcr/abl negative (ACML), XXX
RAS-associated autoimmune leukoproliferative disorder (RALD), XXX
Myelodysplastic syndromes, XXX
Myeloid neoplasms with germline predisposition, XXX
Acute myeloid leukemias, XXX
AMLs with recurrent genetic anomalies, XXX
AMLs with chromosomal anomalies, XXX
AMLs with gene mutations, XXX
AMLs with recurrent genetic anomalies, not recognized by the WHO
classification, XXX
AMLs with myelodysplastic related changes (AML-MRC), XXX
AMLs not otherwise specified, XXX
AML with minimal differentiation, XXX
AML without maturation, XXX
AML with maturation, XXX
Acute myelomonocytic leukemia (AMMoL), XXX
Acute monoblastic or monocytic leukemia (AMoL), XXX
Pure erythroid leukemia (PEL), XXX
Acute megakaryoblastic leukemia (AMKL), XXX
Acute basophilic leukemia (ABL), XXX
Myeloid proliferations associated with Down syndrome, XXX
Transient abnormal myelopoiesis (TAM), XXX
AMLs in patients with Down syndrome, XXX
Blastic plasmacytoid dendritic cell neoplasm (BPDCN/PDCL), XXX
Acute leukemias with ambiguous lineage attribution (ALAL), XXX
Acute undifferentiated leukemias (AUL), XXX
Mixed phenotype acute leukemias (MPAL), XXX
Neoplastic diseases of B and T lymphatic precursors, XXX
B lymphoblastic leukemia/lymphoma,
not otherwise specified (B-ALL/LBLnos), XXX
B lymphoblastic leukemia/lymphoma with recurrent genetic anomalies, XXX
T lymphoblastic leukemia/lymphoma (T-ALL/LBL), XXX
Early T-cell precursors lymphoblastic leukemia (ETP-ALL), XXX
NK lymphoblastic leukemia/lymphoma (NK-ALL/LBL), XXX
Neoplastic diseases of mature B cells, XXX
Chronic lymphocytic leukemia/small
lymphocytic lymphoma (B-CLL/SLL), XXX
Familial B-CLL, XXX
Richter syndrome, XXX
Monoclonal B-cell lymphocytosis (MBL), XXX
B-cell prolymphocytic leukemia (B-PLL), XXX
Lymphoplasmacytic lymphoma (LPL), XXX
Heavy chain disease (HCD), XXX
Gamma heavy chain disease, XXX
Mu heavy chain disease, XXX
Alpha heavy chain disease, XXX
Hairy cell leukemia (HCL), XXX
Hairy cell leukemia, variant (HCL-v), XXX
Hairy cell leukemia, Japanese variant (HCL-J), XXX
Splenic diffuse red pulp lymphoma (SDRPL), XXX
Marginal zone lymphomas (MZL), XXX
Nodal marginal zone lymphoma (NMZL), XXX
Splenic marginal zone lymphoma (SMZL), XXX
Extranodal marginal zone lymphoma (EMZL/MALToma), XXX
Clonal B-cell lymphocytosis with MZL-like phenotype (CBL-MZ), XXX
Follicular lymphoma (FCL), XXX
Testicular follicular lymphoma, XXX
Duodenal type follicular lymphoma, XXX
Pediatric type follicular lymphoma, XXX
Primitive cutaneous follicular lymphoma (PCFL), XXX
Large B-cell lymphoma with IRF4 rearrangement, XXX
Mantle cell lymphoma (MCL), XXX
Blastic mantle cell lymphoma (BMCL), XXX
Leukemic non nodal mantle cell lymphoma, XXX
Diffuse large B-cell lymphomas (DLBCLs), XXX
DLBCL not otherwise specified (DLBCL nos), XXX
T-cell/histiocyte-rich B-cell lymphoma (THRLBCL), XXX
Primary DLBCL of the CNS (PCNSL), XXX
Primary cutaneous DLBCL, “leg type”, XXX
EBV(+) DLBCL nos, XXX
DLBCL associated with chronic inflammation (PAL), XXX
Lymphomatoid granulomatosis (LyG), XXX
Primary mediastinal B-cell lymphoma (PMBCL), XXX
Intravascular large B-cell lymphoma (IVBCL), XXX
ALK-positive large cell lymphoma (ALK(+) LBCL), XXX
Plasmablastic lymphoma (PBL), XXX
Primary effusion lymphoma (PEL), XXX
HHV8-associated lymphoproliferative disorders, XXX
Burkitt lymphoma (BL), XXX
Burkitt leukemia with immature phenotype, XXX
Burkitt-like lymphoma with 11q aberrations, XXX
High grade B-cell lymphoma (HGBL), XXX
Plasma cell neoplasms, XXX
Monoclonal gammopathies of undetermined significance (MGUS), XXX
Multiple myeloma (MM), XXX
Plasma cell leukemia (PCL), XXX
Neoplastic diseases of mature T and NK cells, XXX
T-cell prolymphocytic leukemia (T-PLL), XXX
T-cell large granular lymphocytic leukemia (T-LGL), XXX
Chronic lymphoproliferative disorders of NK cells (CLPD-NK/CNKL), XXX
Aggressive NK-cell leukemia (ANKL), XXX
Adult T-cell leukemia/lymphoma (ATLL), XXX
Extranodal NK/T-cell lymphoma, “nasal type” (ENKTL), XXX
Intestinal T-cell lymphoma (ITCL), XXX
Enteropathy-associated T-cell lymphoma (EATCL), XXX
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), XXX
Indolent gastro-intestinal T lymphoproliferative disorder, XXX
Hepatosplenic T-cell lymphoma (HTSCL), XXX
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL), XXX
Mycosis fungoides (MF), XXX
Sézary syndrome (SS), XXX
Primary cutaneous CD30(+) lymphoproliferative disorders, XXX
Lymphomatoid papulosis (LyP), XXX
Primary cutaneous anaplastic T-cell lymphoma (cALCL), XXX
Primary cutaneous peripheral T-cell lymphoma (PTCL), XXX
Primary cutaneous TCRγδ(+) T-cell lymphoma (PCGD-TCL), XXX
Primary cutaneous CD8(+) aggressive epidermotropic
cytotoxic T-cell lymphoma, XXX
Primary cutaneous acral CD8(+) T-cell lymphoma
Primary cutaneous lymphoma of the medium/small CD4(+) T cells
(PCSM-TCL), XXX
Peripheral T-cell lymphoma, not otherwise specified (PTCLnos), XXX
Nodal lymphomas of follicular T-helper derivation, XXX
Angioimmunoblastic T-cell lymphoma (AITL), XXX
Follicular T-cell lymphoma (FTCL), XXX
Nodal PTCL with follicular T-helper phenotype, XXX
Anaplastic large cell lymphoma ALK(+) (ALK(+) ALCL), XXX
Anaplastic large cell lymphoma ALK(-) (ALK(-) ALCL), XXX
Breast implant-associated anaplastic large cell lymphoma (biaALCL), XXX
Neoplastic diseases of histiocytic and dendritic cells, XXX
Histiocytic sarcoma (HS), XXX
Langerhans cell histiocytosis (LCH), XXX
Indeterminate dendritic cell tumor (IDCT), XXX
Interdigitating dendritic cell sarcoma (IDCS), XXX
Follicular dendritic cell sarcoma (FDCS), XXX
Erdheim-Chester disease (EDC), XXX
3 APPENDIX
Acute leukemias not recognized by the 2016 WHO classification, XXX
Acute leukemia of myeloid/NK precursors (M/NK-AL), XXX
Acute leukemia of myeloid dendritic cells (MDCL), XXX
Acute leukemia of Langerhans cells, XXX
Mature B-cell lymphoblastic leukemia, XXX
Composite lymphomas, XXX
Hypereosinophilic syndrome (HES), lymphocyte variant, XXX
Indolent T lymphoblastic proliferations (iT-LBP), XXX
Polyclonal lymphocytoses of B lymphocytes, XXX
Persistent polyclonal B-cell lymphocytosis (PPBL), XXX
Persistent polyclonal CD5(+) B-cell lymphocytosis, XXX
Persistent polyclonal B-cell lymphocytosis, Japanese (hairy) variant, XXX
Polyclonal plasmacytoses, XXX
Small round (blue) cell tumors (SR(B)CT), XXX
Index
